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Background/Aims: The management of asymptomatic 
erosive esophagitis is controversial. We surveyed physicians’ 
opinions on asymptomatic erosive esophagitis using e-mail. 
Methods: All members of the Korean Society of Neurogastro-
enterology and Motility were invited to answer the question-
naire on the treatment and follow-up of patients with asymp-
tomatic erosive esophagitis by e-mail. Results: A total of 73 
members answered the questionnaire (response rate, 18%). 
As initial management, 41% of respondents chose pharma-
cologic treatment, whereas 59% chose nonpharmacologic 
treatment. In the case of pharmacologic treatment, proton 
pump inhibitors were the preferred medication. The most 
common treatment duration was 4 weeks (43%), followed 
by 8 weeks (38%), and 6 months (11%). Sixty-two percent of 
the respondents recommended follow-up endoscopy annu-
ally, whereas 29% chose no endoscopic follow-up. Thirty-four 
percent of the respondents answered that they would talk 
about reflux-related sleep disturbances. Only 25% of the re-
spondents explained the possibility of Barrett’s esophagus or 
esophageal adenocarcinoma to their patients. Conclusions: 
There are substantial practice variations in the management 
of asymptomatic erosive esophagitis in Korea. (Gut Liver 
2013;7:290-294)
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Therapeutics
INTRODUCTION
Gastroesophageal reflux disease (GERD) can be divided into 
two categories: symptomatic GERD and asymptomatic GERD. 
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Asymptomatic GERD can be defined as the presence of esopha-
geal mucosal injury that is typical for GERD (erosions, peptic 
ulceration, and/or Barrett’s esophagus) during upper endoscopy 
in individuals who lack typical or atypical/extraesophageal 
manifestations of GERD.1
With recent westernization of Korean lifestyles, prevalence of 
GERD in Korea has increased. The prevalence of reflux esopha-
gitis was 1% to 3% in the early period of 1990’s,2,3 4% to 5% 
in the early of period of 2000’s,4,5 9% to 11% in late period of 
2000’s6,7 in routine check-up population, and the prevalence of 
symptoms of reflux esophagitis was 7% to 10% in the middle 
period of 2000’s.8-10
Esophagogastroduodenoscopy is frequently performed as a 
part of gastric cancer screening program in Korea. Accordingly, 
the number of asymptomatic patients with erosive esophagitis 
is increasing continuously. It was reported that 62% to 80% of 
subjects with erosive esophagitis who were diagnosed by en-
doscopy in a routine health check-up program do not have any 
symptoms in Korea.2,4,11 Because little is known about natural 
history of asymptomatic erosive esophagitis, there is currently 
no consensus regarding the best management strategy for as-
ymptomatic erosive reflux esophagitis. In order to examine how 
the patients with asymptomatic erosive esophagitis are managed 
in Korea, we surveyed the physician’s opinion about this issue.
MATERIALS AND METHODS
E-mail invitations were sent to 403 members of the Korean 
Society of Neurogastroenterology and Motility between July 
2009 and August 2009. E-mails were sent three times at 1 week 
interval.
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The questionnaire was composed of two parts. In the first part 
of the survey, participants were asked to describe their practice 
settings and specialities. The second part of the survey evaluated 
endoscopists’ practice patterns regarding treatment, surveillance, 
and explanation to patients of asymptomatic erosive esopha-
gitis, which was confined to the Los Angeles classification A. 
Respondents were asked to choose the best answer from the 
choices relevant to each question, excepting one question about 
how to treat (multiple response questions). The questions are as 
follows: 1) What is your choice for diagnosis code in medical 
insurance claim bills? 2) How do you explain to patient about 
endoscopic finding? 3) How do you treat patients with asymp-
tomatic erosive esophagitis? 4) How long is the duration of your 
treatment? 5) When do you exam following endoscopy? 6) Do 
you ask or explain to patients about sleep disturbance? 7) Do 
you explain to patients about the possibility of Barrett’s esopha-
gus or esophageal adenocarcinoma, or not?
The survey was reviewed independently for content and for-
mat of the questionnaire by several expert endoscopists. Skipped 
questions were not included in the overall response totals. De-
scriptive statistics were used to summarize the responses of the 
survey, including participant characteristics and clinical ques-
tions. Percentages were calculated and used for display in the 
figures. Proportions of the responses were compared between 
private practice and academic groups with the chi-square test. A 
p-value less than 0.05 was considered as statistically significant.
RESULTS
Of the 403 invitations to participate, 73 (response rate, 18.1%) 
physicians responded. The demographics of the respondents are 
shown in Table 1. Among the 73 physicians who responded to 
the survey, 56 (76.7%) practiced in academic medical center, 13 
(17.8%) in general hospital, and four (5.5%) in private practice. 
The specialties of respondents were gastroenterology (90.4%) 
and internal medicine (9.6%), and no other specialties.
In the question about diagnosis code usage in medical re-
cords, the most common response was GERD with esophagitis 
(K21.0, 93.2%). Other responses were GERD without esophagitis 
(K21.9, 4.1%), dyspepsia (K30, 1.4%), and esophagitis (K20, 
1.4%).
The major 41 respondents (56.2%) explained to patients that 
they have GERD but do not need treatment. Twenty-four (32.9%) 
explained that the patients have GERD and need to treat it. A 
small number (2.7%) did not mention anything about endo-
scopic findings of erosive esophagitis.
In the question about initial management of asymptomatic 
esophagitis, 41.1% of respondents chose pharmacologic treat-
ment, whereas 58.9% chose nonpharmacologic treatment. In the 
multiple response question, when asked about how they treat 
patients with asymptomatic erosive esophagitis, the most com-
mon treatment of choice was lifestyle modification (72.6%), fol-
lowed by full-dose proton pump inhibitor (PPI) (35.6%). Eleven 
of the respondents (15.1%) would not talk about treatment 
(Fig. 1). In case of pharmacologic treatment, PPI was preferred 
medication. The most common treatment duration was 4 weeks 
(43.3%), followed by 8 weeks (36.7%), and 6 months (13.3%) 
Fig. 1. Distribution of opinions regarding the treatment for asymp-
tomatic erosive esophagitis (multiple response question). 
PPI, proton pump inhibitor.
Fig. 2. Distribution of opinions regarding the duration of pharmaco-
logic treatment. 
Table 1. Characteristics of Survey Respondents
Characteristic No. (%)
Setting of practice
Academic medical center 56 (76.7)
General hospital 13 (17.8)
Private practice 4 (5.5)
Specialties
Gastroenterology 66 (90.4)
Internal medicine 7 (9.6)
Others 0 (0)
292  Gut and Liver, Vol. 7, No. 3, May 2013
(Fig. 2). Forty-five (61.6%) of the respondents recommended 
follow-up endoscopy annually, whereas 21 (28.8%) chose no 
endoscopic follow-up.
Twenty-five (34.2%) of the respondents answered that they 
would talk about the GERD-related sleep disturbance. Only 18 
(24.7%) of the respondents explain the possibility of Barrett’s 
esophagus or esophageal adenocarcinoma to their patients (Fig. 
3).
DISCUSSION
Asymptomatic GERD is a common phenomenon that in-
volves the incidental finding of erosive esophagitis, Barrett’s 
esophagus, and the evolution of esophageal adenocarcinoma in 
asymptomatic patients. The clinical consequences of asymptom-
atic GERD are various. Son et al.12 reported that most patients 
with asymptomatic reflux esophagitis showed improvement or 
a stable course during 3 years of endoscopic follow-up. This 
report, albeit with many limitations, suggests that the medical 
treatment such as PPI is unnecessary in asymptomatic patients 
with erosive esophagitis. The patients who are diagnosed inci-
dentally with asymptomatic erosive esophagitis are unlikely to 
maintain themselves on antireflux treatment because of poor 
compliance resulting from the lack of disease-related symp-
toms.13 However, there is currently no guidance about what to 
do with asymptomatic erosive esophagitis.
Reflux esophagitis results from the combination of excessive 
gastroesophageal reflux of gastric juice and impaired esophageal 
clearance of the gastric acid. The treatment of reflux esophagitis 
should be titrated to disease severity. Minimal therapy for GERD 
patients is comprised of lifestyle modification, dietary modifica-
tion, as needed antacid use, H2 receptor antagonists, and PPIs. 
Lifestyle modifications are aimed at enhancing esophageal acid 
clearance, minimizing the incidence of reflux events, or both as 
with cessation of smoking and avoidance of late meals. How-
ever, a systematic review of the published literature concluded 
that weight loss and head of bed elevation are effective lifestyle 
interventions for GERD but there is no evidence supporting an 
improvement in GERD measures after cessation of tobacco, al-
cohol, or other dietary interventions.14 Although their effective-
ness has not been extensively evaluated in clinical trials, these 
approaches have been used clinically. Similarly in this survey, 
the most common choice for initial management of asymptom-
atic erosive esophagitis was nonpharmacologic treatment such 
as lifestyle modification.
Among the respondents who chose pharmacologic treatment, 
41.1% chose a PPI (full-dose PPI 35.6%, half-dose PPI 5.5%) 
and 11.0% chose a prokinetic agent, but none chose a H2 re-
ceptor antagonist. Acid-suppressant drugs predominate in the 
treatment of GERD. Many trials have established the efficacy of 
the various PPIs and H2 receptor antagonists in the treatment 
of esophagitis.15,16 PPIs are the first-line of choice in both reflux 
esophagitis and nonerosive reflux disease. In a meta-analysis, 
complete relief from heartburn occurred at a rate of 11.5% per 
week with a PPI compared to 6.4% per week with a H2 receptor 
antagonist.17 On the other hand, asymptomatic Barrett’s esopha-
gus represents no indication for treatment, although recent 
studies have suggested that potent antireflux treatment (such as 
PPIs) may retard neoplastic progression in patients with Barrett’s 
esophagus.18,19 Prokinetic drugs such as bethanechol or meto-
clopramide can be used in the treatment of GERD by increasing 
lower esophageal sphincter pressure, enhancing gastric empty-
ing, or improving peristalsis. However, the currently available 
promotility agents are hampered by side effects that limit their 
use in GERD.20 A guideline on GERD management developed 
by the American Gastroenterological Association Institute rec-
ommends against use of metoclopramide as monotherapy or 
adjunctive therapy because of these side effects.20
In this survey in Korea, 56.2% of respondents explain to pa-
tients that they have GERD, but do not require treatment. And 
58.9% chose nonpharmacologic treatment for initial manage-
ment of asymptomatic erosive esophagitis without medication. 
In spite of these responses, more than half of respondents sur-
vey following endoscopy annually. The need for endoscopy in 
patients with GERD is unsettled. Some experts advocated an en-
doscopy in patients who require continuous maintenance medi-
cal therapy to rule out Barrett’s esophagus.21 In patients without 
Barrett’s esophagus on an initial examination, the cancer risk 
is too low to justify a follow-up endoscopy. Exceptions are pa-
tients who develop bleeding, dysphagia, or a significant change 
in symptoms while on effective therapy.
Sleep and GERD have a bidirectional relationship in which 
Fig. 3. Distribution of opinions 
regarding discussing the following 
with patients: (A) sleep disturbances 
and (B) the possibility of Barrett’s 
esophagus or esophageal adenocar-
cinoma.
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GERD adversely affects the quality of sleep, and poor quality of 
sleep worsens GERD.22-24 Unfortunately, the clinical features of 
sleep disorders including obstructive sleep apnea are nonspecific 
and the diagnostic accuracy of clinicians’ subjective impres-
sion is poor.25 Recent studies have shown that, even in patients 
without nighttime heartburn, gastroesophageal reflux may re-
sult in sleep disturbances.26 It suggests that the presence of sleep 
disturbances and poor quality of sleep could be clinical clues for 
identifying patients with asymptomatic GERD. However, there is 
little interest in this area, unlike extraesophageal symptoms such 
as cough, asthma or laryngitis in Korea. In this survey, only 
34% were explaining to the patients about sleep disturbance.
Barrett’s esophagus is a metaplastic change of the esophageal 
mucosa, such that the normal squamous epithelium is replaced 
by specialized columnar epithelium.27 The condition develops as 
a consequence of chronic GERD, and predisposes to the devel-
opment of adenocarcinoma of the esophagus. Estimates of the 
frequency of Barrett’s esophagus in the general population have 
varied widely ranging from 0.9% to 4.5% depending in part 
upon the population studied and the definitions used.28,29 To de-
crease mortality from esophageal adenocarcinoma, it has been 
proposed that patients with GERD symptoms should be screened 
endoscopically for Barrett’s esophagus.21,30 However, a signifi-
cant number of patients presenting with adenocarcinoma of 
the esophagus don’t have any GERD-related symptoms such as 
heartburn or regurgitation during their lifetime.31 In other stud-
ies, fewer than 5% were known to have had Barrett’s esophagus 
before they presented with symptoms of esophageal cancer.32 It 
is not clear that patients who have Barrett’s esophagus benefit 
from surveillance. In addition, there is little evidence that these 
programs have prevented deaths from esophageal adenocarci-
noma. Even more, because the epidemiological study about re-
lationship between GERD and Barrett’s esophagus or esophageal 
adenocarcinoma is insufficient in Korea, explanation of risk like 
this on the basis of just endoscopic finding of erosive esophagi-
tis is maybe unnecessary. In this survey, only 25% was explain-
ing to the patients about possibility of Barrett’s esophagus or 
esophageal adenocarcinoma.
Practice variation in countries other than Korea is yet to be 
reported. Fass and Dickman1 suggested that the clinical implica-
tions of silent GERD are vast, but no specific treatment guide-
line was recommended. According to Lu33 in Taiwan, whether to 
treat asymptomatic GERD patients is an open question.
One of the limitations of our study is that the opinions of 
members of the Korean Society of Neurogastroenterology and 
Motility do not necessarily reflect the opinions and practices 
of endoscopists nationwide and that only 18.1% of the group 
responded to the survey. There are also inherent limitations to 
a multiple choice survey; however, several of our questions al-
lowed for write-in responses. Additionally, given the anonymity 
of our survey design, we were unable to characterize differences 
between respondents and nonrespondents that may affect the 
survey results.
In summary, there are substantial practice variations in the 
management of asymptomatic erosive esophagitis in Korea. A 
majority of our survey respondents prefer nonpharmacologic 
treatment such as lifestyle modification to pharmacologic treat-
ment such as PPI. Practice patterns of endoscopic surveillance 
are variable.
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